FLOMAX has been proven effective and well tolerated in a number of clinical trials. Browse this section to learn about the trial designs and see selected trial results.
A 13-Week, Pivotal Double-Blind Trial (US 92-03A)
A Second 13-Week, Pivotal Double-Blind Trial (US 93-01)
Efficacy: Long-term Trial Data
Double-Blind Extension Trial (US 92-03B)
Six-Year Efficacy and Safety Study (527.2)
Efficacy: Comparative Trial Data
Tamsulosin vs Terazosin: Randomized, Open-Label, 11-Week Clinical Trial (527.17)
ALFOTAM Trial
Pivotal Safety Studies (US 92-03A and US 93-01)
Six-Year Efficacy and Safety Trial (527.2)
Safety: Comparative Trial Data
Tamsulosin vs. Terazosin: Randomized, Open-Label, 11-Week Clinical Trial (527.17)
ALFOTAM Trial
 |
Talking with your patients about BPH |
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
